Stanford, CALIFORNIA10 Active Studies

Ankylosing Spondylitis Clinical Trials in Stanford, CALIFORNIA

Find 10 actively recruiting ankylosing spondylitis clinical trials in Stanford, CALIFORNIA. Connect with local research sites and explore new treatment options.

10
Active Trials
9
Sponsors
3,538
Enrolling

Recruiting Ankylosing Spondylitis Studies in Stanford

RecruitingStanford, CALIFORNIANCT03970447

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple...

1,280 participants
Global Coalition for Adaptive Research
View Study Details
RecruitingStanford, CALIFORNIANCT04064060

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

A Phase 3b, open-label, single-arm, rollover study to evaluate the long-term safety of luspatercept, to the following participants: * Participants receiving luspatercept on a parent protocol at the t...

665 participants
Celgene
View Study Details
RecruitingStanford, CALIFORNIANCT03424005

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer. The study will be perform...

580 participants
Hoffmann-La Roche
View Study Details
RecruitingStanford, CALIFORNIANCT04802759

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with breast cancer. The study is designed with the flexibility to open new treatment arms as new treatments be...

316 participants
Hoffmann-La Roche
View Study Details
RecruitingStanford, CALIFORNIANCT06418711

ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

This clinical trial is designed to compare the efficacy and safety of Clofazimine Inhalation Suspension versus placebo when added to guideline-based therapy (GBT)...

234 participants
Mannkind Corporation
View Study Details
RecruitingStanford, CALIFORNIANCT04996875

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Asso...

140 participants
Cogent Biosciences, Inc.
View Study Details
RecruitingStanford, CALIFORNIANCT06388564

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

This study will be conducted to determine the preliminary efficacy of axatilimab in combination with ruxolitinib and to assess the contribution of axatilimab to the combination treatment effect in par...

120 participants
Incyte Corporation
View Study Details
RecruitingStanford, CALIFORNIANCT03382977

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

The purpose of this study is to assess the safety and tolerability of VBI-1901 in subjects with recurrent malignant gliomas (glioblastoma, or GBM)....

98 participants
VBI Vaccines Inc.
View Study Details
RecruitingStanford, CALIFORNIANCT06517641

Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia

BMT CTN 2207 will investigate the use of marrow transplantation for treatment of severe aplastic anemia that has not previously been treated....

60 participants
Medical College of Wisconsin
View Study Details
RecruitingStanford, CALIFORNIANCT04523727

Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease

This study will be conducted to assess the safety and tolerability of ferric citrate in pediatric participants with hyperphosphatemia related to chronic kidney disease (CKD)....

45 participants
Keryx Biopharmaceuticals
View Study Details

About Ankylosing Spondylitis Clinical Trials in Stanford

Ankylosing spondylitis is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, causing pain, stiffness, and potentially spinal fusion. It typically begins in early adulthood. Treatment includes NSAIDs, biologics (TNF and IL-17 inhibitors), and physical therapy.

There are currently 10 ankylosing spondylitis clinical trials recruiting participants in Stanford, CALIFORNIA. These studies are seeking a combined 3,538 participants. Research is being sponsored by Global Coalition for Adaptive Research, Celgene, Hoffmann-La Roche and 6 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Ankylosing Spondylitis Clinical Trials in Stanford — FAQ

Are there ankylosing spondylitis clinical trials in Stanford?

Yes, there are 10 ankylosing spondylitis clinical trials currently recruiting in Stanford, CALIFORNIA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Stanford?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Stanford research site will contact you about next steps.

Are clinical trials in Stanford free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Stanford studies also compensate for your time and travel.

What ankylosing spondylitis treatments are being tested?

The 10 active trials in Stanford are testing new therapies including novel drugs, biologics, and treatment approaches for ankylosing spondylitis.

Data updated March 2, 2026 from ClinicalTrials.gov